Earnings results for Biocept (NASDAQ:BIOC)
Biocept, Inc. is expected* to report earnings on 11/12/2020 after market close. The report will be for the fiscal Quarter ending Sep 2020. According to Zacks Investment Research, based on 1 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.48. The reported EPS for the same quarter last year was $-2.5.
Biocept last issued its quarterly earnings results on August 12th, 2020. The medical research company reported ($0.50) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.50). The firm earned $0.92 million during the quarter, compared to the consensus estimate of $1.30 million. Biocept has generated ($12.20) earnings per share over the last year. Biocept has confirmed that its next quarterly earnings report will be published on Thursday, November 12th, 2020.
Analyst Opinion on Biocept (NASDAQ:BIOC)
2 Wall Street analysts have issued ratings and price targets for Biocept in the last 12 months. Their average twelve-month price target is $20.00, predicting that the stock has a possible upside of 305.68%. The high price target for BIOC is $20.00 and the low price target for BIOC is $20.00. There are currently 2 buy ratings for the stock, resulting in a consensus rating of “Buy.”
Biocept has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings. According to analysts’ consensus price target of $20.00, Biocept has a forecasted upside of 305.7% from its current price of $4.93. Biocept has received no research coverage in the past 90 days.
Dividend Strength: Biocept (NASDAQ:BIOC)
Biocept does not currently pay a dividend. Biocept does not have a long track record of dividend growth.
Insiders buying/selling: Biocept (NASDAQ:BIOC)
In the past three months, Biocept insiders have not sold or bought any company stock. Only 0.40% of the stock of Biocept is held by insiders. Only 10.24% of the stock of Biocept is held by institutions.
Earnings and Valuation of Biocept (NASDAQ:BIOC
Earnings for Biocept are expected to decrease in the coming year, from ($0.42) to ($1.73) per share. The P/E ratio of Biocept is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Biocept is -0.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Biocept has a P/B Ratio of 2.10. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.
More latest stories: here